Nevertheless, upon intravenous injection, the shield in combination with the adapter increased the tumor-to-liver ratio for the EGFR+ tumor model by a factor of 2500, and for the HER2+ tumor model 300-fold compared to HAdV5HVR7 alone, in both cases resulting in a tumor-to-liver ratio of >2. The gene discussed is EGFR; the disease is neoplasm.